Bruker Corporation (NASDAQ: BRKR)
Q2 2017 Earnings Presentation
Frank Laukien, President & CEO
Anthony Mattacchione, SVP & CFO
Miroslava Minkova, Head of Investor RelationsAugust 3, 2017
Innovation with Integrity

BRUKER CORPORATION
Safe Harbor & Reg. G Statement
Any statements contained in this presentation that do not describe historical facts may constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on current expectations, but are subject to
risks and uncertainties that could cause actual results to differ materially from those indicated, including,
but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy
and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the
future, fluctuations in foreign currency exchange rates, our ability to successfully implement restructuring
initiatives, changing technologies, product development and market acceptance of our products, the cost
and pricing of our products, manufacturing, competition, dependence on collaborative partners, key
suppliers and contract manufacturers, capital spending and government funding policies, changes in
governmental regulations, the use and protection of intellectual property rights, litigation, and other risk
factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC.
These and other factors are identified and described in more detail in our filings with the SEC, including,
without limitation, our annual report on Form 10-K for the year ended December 31, 2016 and
subsequently filed Quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to
update these forward-looking statements other than as required by law. We will also be referencing non-
GAAP financial measures in this presentation. A reconciliation of non-GAAP to GAAP results is available in
our earnings press release and in this presentation.
2

Business Update
Q2-2017 & H1-2017
3

Q2-2017 Performance
 Revenue increase of +$43M, or +11.6% y-o-y in
comparison with weak Q2-16
− Acquisitions add +5.8% y-o-y
− FX lowers revenue by -1.8% y-o-y
− Organic revenue up +7.6% y-o-y, with growth at
CALID, BioSpin and very strong BEST growth
 Non-GAAP gross margin decreases -100 bps y-o-y
 Non-GAAP operating margin expands +170 bps y-o-y
 GAAP EPS of $0.15, compared to $0.09 in Q2-16
 Non-GAAP EPS of $0.23, compared to $0.20 in Q2-16
− Non-GAAP eff. tax rate 24.2%, vs. 12.0% in Q2-16
Q2 Financials
4
Revenues [$M]
372
415
Q2-16 Q2-17
Non-GAAP EPS
Q2-2017: Solid revenue, operating income and
EPS growth year-over-year
+11.6%
+15%
$0.20
$0.23
Q2-16
Q2-17

H1-2017 Performance
 Continued y-o-y improvements in European orders,
and evidence of improved industrial demand
 Revenue increase of +$53M, or +7.1% y-o-y
− Acquisitions add +5.5% y-o-y
− FX lowers revenue by -1.8% y-o-y
− Organic revenue up +3.4% y-o-y, with growth at
BioSpin, CALID and strong growth at BEST
 Non-GAAP gross margin about flat y-o-y
 Non-GAAP operating margin expands +90 bps y-o-y
 GAAP EPS of $0.28, compared to $0.23 in H1-16
 Non-GAAP EPS of $0.41, unchanged from H1-16
− Non-GAAP eff. tax rate 27.2%, vs. 15.0% in H1-16
H1 Financials
5
Revenues [$M]
747 800
H1-16 H1-17
Non-GAAP EPS
H1-2017: Back to positive organic growth,
operating margins higher
+7.1%
0%
$0.41
$0.41
H1-16
H1-17

Bruker BIOSPIN Group
 BIOSPIN low single digit constant currency revenue growth; operating
margins lower on mix
 NMR steady, despite challenging comp (including 1GHz NMR revenue
in Q1-16)
 PCI revenue improves with good Q2 execution; PCI market recovery
encouraging
 Continued strong after-market revenue growth with LabScapeTM
 CALID low single digit constant currency revenue growth; operating
margins significantly better y-o-y, with improving revenue and 2016
restructuring
 Daltonics up mid single digits in constant currency; 2016 restructuring
drives higher margins
 Optics revenues grow in mid single digits; operating margins higher;
evidence of improved applied and industrial markets
 Detection revenue down due to large Middle East contract in Q1-16
GROUP OVERVIEW:
H1-2017 Operating Performance
6
Bruker CALID Group

Bruker NANO Group
 NANO mid single digit constant currency revenue growth, helped by
Hysitron acquisition (January 2017); improvements in industrial and
European orders
 AXS revenue strengthens significantly after weak 2016; higher academic
and industrial volume, plus 2016 restructuring drive margin expansion
 Semiconductor metrology (‘Semi’) revenue and margins below prior year
due to lower opening backlog; orders up and expect good H2-17 in Semi
 Nano Surfaces revenue grows with Hysitron addition
BEST Segment
 BEST revenue substantially higher, with >20% organic growth plus
inorganic growth from B-OST acquisition (November 2016); BEST
gross margin is inherently lower than BSI gross margins;
 Demand for superconducting materials and timing of large research
projects drive BEST results
 B-OST performance on target; productivity investments will take time
GROUP OVERVIEW:
H1-17 Operating Performance
7

Innovation with Integrity
Innovation and Portfolio Expansion in Microbiology:
IR BiotyperTM Solution for Microbial Strain Typing
8
New IR BiotyperTM Solution
 Unique benchtop system for microbial
strain typing based on FT-IR spectroscopy
 For in-house workflows in hospital
hygiene and healthcare infection control
testing
 Complementary to MALDI Biotyper®
microbial ID workflow
 Launched at ASM Microbe 2017 in June

Innovation with Integrity
Value-creating M&A and Portfolio Transformation in
Cell Biology and Neuroscience:
New Luxendo™ Light-Sheet Microscopy Product Line
9
Luxendo Light-Sheet Microscopy:
Proprietary single plane illumination
microscopy (SPIM) reduces acquisition
times compared to confocal microscopy
For live cell imaging, SPIM reduces
photo-toxicity on living specimen
Enables new research in embryology,
live-cell imaging, and neuroscience
Complements Bruker products in multi-
photon and super-resolution cell and
neuroscience fluorescence microscopy
Bruker acquired Luxendo in May 2017

2017 Key Priorities
Resume Revenue Growth via a combination of
organic growth and M&A contributions
Sustain Margin Expansion as we continue our
Operational & Commercial Excellence journey
Continue to Strengthen Systems and insights by
harmonizing processes, ERP and CRM platforms
Invest in profitable growth: six key high-growth,
high-margin initiatives for portfolio transformation
Thoughtfully Deploy Capital for sustainable
shareholder returns
10

Financial Update
Q2-2017 & H1-2017
11

NON-GAAP FINANCIAL PERFORMANCE:
Q2-2017 Overview
[$ m, except EPS] Q2-2017 Q2-2016 Δ
Revenues 414.9 371.7 +11.6%
Operating Income 51.7 40.0 +29%
Margin (%) 12.5% 10.8% +170ps
Non-GAAP EPS $0.23 $0.20 +15%
Free Cash Flow -26.8 8.9 -35.7m
[$ m] Jun 30, 2017 Jun 30, 2016 Δ
Net Cash 9.5 77.4 -88%
Working capital (WC)* 653.8 589.9 +11%
WC-to-revenue ratio $0.39 $0.36 -8%
12
COMMENTS
 Reported revenue +11.6%,
strong organic growth
 Operating margin up +170
bps y/y
 2016 restructuring
contributes to operating
margin expansion
 EPS up 15% despite
unusually low Q2-16 tax rate
 Free cash flow -$26.8M
 Use of cash for buybacks,
dividends and M&A result in
lower net cash balance
 Working capital up +11%
with acquisitions
* WC = (Accounts Receivable + Inventory - Accounts Payable)

Q2 2016 Organic Currency Portfolio Q2 2017
$371.7M $414.9M
Q2-2017 Revenue Bridge
Organic Currency Portfolio Total
+7.6% -1.8% +5.8% +11.6%
 Reported revenue
+11.6%
 Organic revenue up
+7.6%, reflecting y/y
increases at CALID,
BioSpin and BEST
 B-OST, Hysitron and
InVivo acquisitions add
+5.8% to revenue growth
 FX negative by -$6.8M, or
-1.8%
13
Q2-2017 DRIVERS
Q2-2017 Revenue Bridge [$M]
+$28.4M -$6.8M +$21.6M
Q2-2017 Revenue for Bruker Corporation

Q2-2017 Non-GAAP Results
[$ m, except EPS] Q2-2017 Q2-2016 Δ
Total Revenues 414.9 371.7 +11.6%
Gross Profit 193.3 176.9 +9%
Margin (% of revenues) 46.6% 47.6% -100 bps
SG&A -100.9 -100.1 +1%
(% of revenues) 24.3% 26.9%
R&D -40.7 -36.8 +11%
(% of revenues) 9.8% 9.9%
Operating Income 51.7 40.0 +29%
(% of revenues) 12.5% 10.8% +170 bps
Tax Rate 24.2% 12.0% +1220 bps
Net Income* 36.1 32.6 +11%
EPS $0.23 $0.20 +15%
Shares Outstanding 160.4 162.4 -1%
 Gross margin down -100 bps:
– Higher BEST revenue with
inherently lower gross margins
– BioSpin mix with more low field
NMR in Q2-17
 R&D up 11% y/y on selected
investments and acquisitions
 Operating margin up +170 bps,
with volume and operational
improvements at Daltonics & AXS
 Q2-2017 effective tax rate of
24.2% up from 12% in Q2-16
(2016 valuation allowance
reversals)
 EPS up 15% y/y as revenue
growth and higher operating
margins more than offset
challenging tax comparison
 Share count lower on share
repurchases
14
COMMENTS
* Attributable to BrukerSum of items may not total due to rounding

H1 2016 Organic Currency Portfolio H1 2017
$747.1M $799.8M
H1-2017 Revenue Bridge
Organic Currency Portfolio Total
+3.4% -1.8% +5.5% +7.1%
 Reported revenue +7.1%
 Organic revenue growth
+3.4%, reflecting growth
at BioSpin, CALID and
BEST
 B-OST, Hysitron and
InVivo acquisitions add
+5.5% to revenue growth
 FX negative by -$14.1M,
or -1.8%
15
H1-2017 DRIVERS
H1-2017 Revenue Bridge [$M]
+$25.5M -$14.1M
+$41.3M
H1-2017 Revenue for Bruker Corporation

H1-2017 Non-GAAP Results
[$ m, except EPS] H1 2017 H1 2016 Δ
Total Revenues 799.8 747.1 +7.1%
Gross Profit 376.7 352.3 +7%
Margin (% of revenues) 47.1% 47.2% -5 bps
SG&A -197.5 -192.1 +3%
(% of revenues) 24.7% 25.7%
R&D -78.3 -72.9 +7%
(% of revenues) 9.8% 9.8%
Operating Income 100.9 87.3 +16%
(% of revenues) 12.6% 11.7% +90 bps
Tax Rate 27.2% 15.0% 1220 bps
Net Income* 66.0 66.9 -1%
EPS $0.41 $0.41 0%
Shares Outstanding 160.4 163.3 -2%
 Gross margin flat. Higher
Daltonics and AXS volume
offset by more BEST revenue,
and BioSpin mix effects
 Operating margin up +90 bps,
with higher revenue and
operational improvements at
Daltonics and AXS
 H1-2017 effective tax rate
27.2% vs. 15.0% in H1-16
(2016 valuation allowance
reversals); full FY17 rate ~25%
 EPS flat y/y despite unusually
low effective tax rate in H1-16
 Share count lower due to share
repurchases
16
COMMENTS
* Attributable to BrukerSum of items may not total due to rounding

H1-2017 Cash Flow
[$ m] H1-2017 H1-2016 Δ
Net Income 45.7 38.4 +7.3
Depreciation & amortization 31.1 26.7 +4.4
Changes in working capital* -20.0 -15.0 -5.0
Other -41.4 -46.0 +4.6
Operating cash flow 15.4 4.1 +11.3
Capital expenditures -21.1 -17.2 -3.9
Free cash flow -5.7 -13.1 +7.4
 Y-o-y free cash flow
improvements driven by:
– Operating cash flow
higher due to higher net
income and lower tax
payments
– Uptick in capital
expenditures
17
COMMENTS
* WC = (Accounts Receivable + Inventory - Accounts Payable)

2017 Outlook
18

FY 2017 Guidance
Revenue Growth y-o-y +4.5% to +6.0%
Non-GAAP Operating
Margin Expansion y-o-y(1)(2)
+40 bps to +70 bps
Non-GAAP EPS $1.08 - $1.12
19
FY 2017 Guidance: Adjusting Outlook for Mid-Year
Performance and Changes in FX
 Organic revenue growth of
+1.5% to +2% (updated)
 Acquisition revenue
growth: +3.5% to +4%
 FX revenue headwind:
-0.5% to 0% (updated)
 Non-GAAP tax rate: ~25%
 Fully diluted share count:
~160M shares (updated)
 Capex: ~$45M
 FX assumptions as of
June 30, 2017:
USD = 112.4 Yen
EUR = 1.14 USD
CHF = 1.04 USD
2017 ASSUMPTIONS
(1) From a FY16 non-GAAP operating margin of 14.8%.
(2)Includes approximately -40 bps cumulative negative effect from 2016 and 2017
acquisitions. Excluding acquisitions, Bruker underlying non-GAAP operating margin
expected to expand by +80 bps to +110 bps in FY 2017.

Appendix
20

Q2-2017 GAAP Results
[$M, except EPS] Q2 2017 Q2 2016 Δ
Total Revenues 414.9 371.7 +12%
Gross Profit 183.4 170.1 +8%
Margin (% of sales) 44.2% 45.8%
SG&A -102.8 -100.9 +2%
(% of revenues) 24.8% 27.1%
R&D -40.7 -36.8 +11%
(% of revenues) 9.8% 9.9%
Operating Income 33.5 20.4 +64%
(% of revenues) 8.1% 5.5%
Net Income* 23.4 14.5 +61%
EPS $0.15 $0.09 +67%
Shares Outstanding 160.4 162.4 -1%
21
* Attributable to BrukerSum of items may not total due to rounding

Q2-2017 Reconciliation of GAAP and
Non-GAAP Results
[$M, except EPS] Q2 2017 Q2 2016
GAAP Operating Income 33.5 20.4
Restructuring Costs 3.8 3.7
Acquisition-Related Costs 5.9 8.1
Purchased Intangible Amortization 7.5 5.4
Other Costs 1.0 2.4
TOTAL 18.2 19.6
Non-GAAP Operating Income 51.7 40.0
Non-GAAP Interest & Other Expense, net -3.3 -2.6
Non GAAP Profit Before Tax 48.4 37.4
Non-GAAP Income Tax Provision -11.7 -4.5
Non-GAAP Tax Rate 24.2% 12.0%
Minority Interest -0.6 -0.3
Non-GAAP Net Income* 36.1 32.6
Non-GAAP EPS $0.23 $0.20
22
Sum of items may not total due to rounding
*Attributable to Bruker

H1-2017 GAAP Results
[$M, except EPS] H1 2017 H1 2016 Δ
Total Revenues 799.8 747.1 +7%
Gross Profit 359.8 336.9 +7%
Margin (% of sales) 45.0% 45.1%
SG&A -200.9 -193.6 +4%
(% of revenues) 25.1% 25.9%
R&D -78.3 -72.9 +7%
(% of revenues) 9.8% 9.8%
Operating Income 71.1 54.4 +31%
(% of revenues) 8.9% 7.3%
Net Income* 45.0 38.1 +18%
EPS $0.28 $0.23 +22%
Shares Outstanding 160.4 163.3 -2%
23
* Attributable to BrukerSum of items may not total due to rounding

H1-2017 Reconciliation of GAAP and
Non-GAAP Results
[$M, except EPS] H1 2017 H1 2016
GAAP Operating Income 71.1 54.4
Restructuring Costs 3.9 7.5
Acquisition-Related Costs 8.7 10.0
Purchased Intangible Amortization 14.4 10.8
Other Costs 2.8 4.6
TOTAL 29.8 32.9
Non-GAAP Operating Income 100.9 87.3
Non-GAAP Interest & Other Expense, net -9.3 -8.2
Non GAAP Profit Before Tax 91.6 79.1
Non-GAAP Income Tax Provision -24.9 -11.9
Non-GAAP Tax Rate 27.2% 15.0%
Minority Interest -0.7 -0.3
Non-GAAP Net Income* 66.0 66.9
Non-GAAP EPS $0.41 $0.41
24
Sum of items may not total due to rounding
*Attributable to Bruker

Q2-2017 Cash Flow
[$ m] Q2 2017 Q2 2016 Δ
Net Income 24.0 14.8 +9.2
Depreciation & amortization 16.0 13.5 +2.5
Changes in working capital* -20.5 -13.7 -6.8
Other -36.7 3.5 -40.2
Operating cash flow -17.2 18.1 -35.3
Capital expenditures -9.6 -9.2 -0.4
Free cash flow -26.8 8.9 -35.7
 Free cash flow lower y/y
driven by:
– Increased use of cash for
working capital needs
– Timing of customer
advances
– Timing of incentive
compensation payments
(in Q2-17 vs. in Q1-16)
25
COMMENTS
* WC = (Accounts Receivable + Inventory - Accounts Payable)

Balance Sheet
[$M]
Jun 30,
2017
Dec 31,
2016
Jun 30,
2016
Cash, Cash Equivalents &
Short-term Investments
440.3 500.3 420.4
Financial Debt 430.8 411.7 343.0
Net Cash 9.5 88.6 77.4
26
[$M]
Jun 30,
2017
Dec 31,
2016
Jun 30,
2016
Total Assets 1,912.9 1,808.4 1,720.5
Working Capital* 653.8 598.2 589.9
Intangibles, Net & Other
Long-Term Assets
360.5 293.4 268.3
* WC = (Accounts Receivable + Inventory - Accounts Payable)

Q2-17 GAAP SEGMENT RESULTS:
BSI and BEST GAAP Performance
[$ m] Q2-2017 Q2-2016 Δ
REVENUE
Scientific Instruments (BSI) 362.5 345.8 +5%
Organic Revenue Growth (%) +4.4% -8.7%
Energy & Supercon Technologies (BEST) 54.0 28.5 +89%
Organic Revenue Growth (%) +43.2% -8.9%
Corporate Eliminations -1.6 -2.6
Total Revenue 414.9 371.7 +11.6%
OPERATING INCOME
Scientific Instruments (BSI) 30.5 18.9 +61%
Energy & Supercon Technologies (BEST) 3.0 1.4 +114%
Corporate Eliminations 0.0 0.1
Total Operating Income 33.5 20.4 +64%
27
Sum of items may not total due to rounding